NORTH CHINA PHARMACEUTICAL COMPANY.LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.91 CNY | +3.81% |
|
+9.84% | -13.86% |
| Sales 2022 | 10.5B 1.45B 121B | Sales 2023 | 10.12B 1.4B 116B | Capitalization | 9.78B 1.35B 113B |
|---|---|---|---|---|---|
| Net income 2022 | -689M -95.09M -7.93B | Net income 2023 | 4M 552K 46.03M | EV / Sales 2022 | 1.94 x |
| Net Debt 2022 | 9.37B 1.29B 108B | Net Debt 2023 | 10.16B 1.4B 117B | EV / Sales 2023 | 1.97 x |
| P/E ratio 2022 |
-15.9
x | P/E ratio 2023 |
1,900
x | Employees | 10,159 |
| Yield 2022 * |
-
| Yield 2023 |
0.18% | Free-Float | 41.8% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.81% | ||
| 1 week | +9.84% | ||
| Current month | +3.37% | ||
| 1 month | +4.69% | ||
| 3 months | -0.61% | ||
| 6 months | -11.05% | ||
| Current year | -13.86% |
1 week
4.41
4.91
1 month
4.364.91
Current year
3.835.77
1 year
3.836.66
3 years
3.8313.45
5 years
3.8320.24
10 years
3.8320.24
| Managers | Title | Age | Since |
|---|---|---|---|
Xin Yan Liu
CEO | Chief Executive Officer | 54 | 28/18/28 |
Jian Jun Li
DFI | Director of Finance/CFO | 53 | 01/09/01 |
Suo Qing Zhang
BRD | Director/Board Member | 54 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yao Cao
BRD | Director/Board Member | 47 | 22/16/22 |
De Min Zhou
BRD | Director/Board Member | 58 | 22/19/22 |
Xiao Han Liu
BRD | Director/Board Member | 69 | 22/19/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 4.91 | +3.81% | 19,706,480 |
| 25/24/25 | 4.73 | +2.38% | 11,367,150 |
| 24/24/24 | 4.62 | +1.09% | 7,446,000 |
| 23/24/23 | 4.57 | +0.88% | 7,583,500 |
| 22/24/22 | 4.53 | +1.34% | 9,055,060 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
North China Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production and sales of pharmaceutical products. The Company's main products include anti-infective drugs, nephrology and immunomodulatory drugs, biotechnology drugs, cardiovascular and cerebrovascular and immunomodulatory agents, vitamins and health consumer products, nervous and blood system drugs, pharmaceutical intermediates, anti-epidemic drugs, pesticides and Veterinary drugs. The Company is also engaged in pharmaceutical and other logistics trade pharmaceuticals. The Company's products are mainly used in chemical pharmaceuticals, modern biotechnology drugs, vitamins and health consumer products, bioagricultural and veterinary drugs and other fields. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.86% | 1.16B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600812 Stock
